title: Anxiety as a predictor of treatment outcome in children and adolescents with depression.
abstract: OBJECTIVE
  The aim of this study was to examine the impact of co-morbid illnesses on treatment outcomes in depressed children and adolescents aged 7-17 who were treated with fluoxetine.
  
  
  METHODS
  This data set was drawn from two large clinical trials involving children and adolescents with depression. Subjects with a diagnosis of major depressive disorder and depressive symptoms of at least moderate severity as defined by a Children's Depression Rating Score, Revised (CDRS-R) total score >or=40 and a Clinical Global Impressions-Severity (CGI-S) rating >or=4 were included. Subjects were randomized to receive fluoxetine or placebo over an 8-week period. Predictor analyses examining two primary outcomes were conducted: (1) Response based on Clinical Global Impressions-Improvement (CGI-I) score of 1 or 2, and (2) remission based on CDRS-R score of <or=28. Logistic regression models were run to assess whether anxiety disorders were a predictor of response or remission.
  
  
  RESULTS
  A total of 309 study participants were included. The only factor found to influence response was treatment with fluoxetine (p = 0.022, odds ratio [OR] = 2.08, 95% confidence interval [CI] 1.30, 3.31). Several factors were found to influence remission: Treatment with fluoxetine (p < 0.0001, OR = 3.17, 95% CI 1.80, 5.57), gender (p = 0.024, OR = 1.90, 95% CI 1.09, 3.30), and number of co-morbid diagnoses (p = 0.026, OR 0.73, 95% CI 0.55, 0.96).
  
  
  CONCLUSIONS
  Anxiety disorders alone did not predict response or remission, but the total number of co-morbid illnesses was associated with remission in depressed children and adolescents treated with fluoxetine.
authors.affiliation: Department of Psychiatry, University of Toronto, Toronto, Canada. dramy.cheung@gmail.com
authors.forename: Amy
authors.initials: A
authors.lastname: Cheung
authors.forename: Taryn
authors.initials: T
authors.lastname: Mayes
authors.forename: Anthony
authors.initials: A
authors.lastname: Levitt
authors.forename: Ayal
authors.initials: A
authors.lastname: Schaffer
authors.forename: Erin
authors.initials: E
authors.lastname: Michalak
authors.forename: Alex
authors.initials: A
authors.lastname: Kiss
authors.forename: Graham
authors.initials: G
authors.lastname: Emslie
mesh_terms: D000293:Adolescent; D018687:Antidepressive Agents, Second-Generation / Q000627:therapeutic use*; D001008:Anxiety Disorders / Q000150:complications*; D002648:Child; D003865:Major Depressive Disorder / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D005260:Female; D005473:Fluoxetine / Q000627:therapeutic use*; D006801:Humans; D016015:Logistic Models; D008297:Male; D016032:Randomized Controlled Trials as Topic; D012008:Recurrence; D012720:Severity of Illness Index; D012737:Sex Factors; D016896:Treatment Outcome
chemical_list: D018687:Antidepressive Agents, Second-Generation; D005473:Fluoxetine